HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SRI 63-441
structure given in first source; PAF antagonist
Also Known As:
1-(2-(hydroxy((tetrahydro-5-((octadecylaminocarbonyl)oxy)methyl)furan-2-yl)methoxyphosphinyloxy)ethyl)quinolinium; SDZ 63-441; SRI-63-441; Sandoz 63-441
Networked:
23
relevant articles (
2
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Quinolines: 146
Quinolinium Compounds: 1
SRI 63-441: 23
Related Diseases
1.
Anterior Uveitis
02/01/1995 - "
SRI 63-441 reduced the anterior uveitis at 24 h and to a lesser extent at 48 h; it also reduced the posterior uveitis at 48 h.
"
07/01/1991 - "
Although all of the treatments significantly reduced the severity of anterior uveitis, SRI 63-441 plus indomethacin was the most effective, indomethacin and naproxen were intermediately effective, and SRI 63-441 was the least effective.
"
2.
Thrombocytopenia (Thrombopenia)
09/01/1988 - "
In a splenectomized mouse bioassay 6 micrograms alprazolam inhibited, for 3 h, the thrombocytopenia induced by 0.1 micrograms PAF; 4 micrograms iloprost and 0.5 microgram SRI 63-441 were effective for 6 and 12h respectively.
"
3.
Endotoxemia
06/01/1989 - "
These results suggest that PAF may cause increased TxA2 release during endotoxemia, which may not be preventable by use of the PAF-receptor antagonist SRI-63-441, which is capable of inhibiting PAF-induced aggregation of equine platelets.
"
12/01/1990 - "
SRI 63-441 attenuated the acute leukopenia noted after endotoxemia.
"
12/01/1988 - "
Effects of platelet-activating factor antagonist SRI 63-441 on endotoxemia in sheep.
"
07/01/1989 - "
A therapeutic role for the PAF antagonists BN 52021 and SDZ 63-441 is suggested in endotoxemia, anaphylaxis, and other disease states in which increased release of PAF contributes to key hemodynamic derangements.
"
12/01/1988 - "
We investigated whether platelet-activating factor (PAF) mediates endotoxin-induced systemic and pulmonary vascular derangements by studying the effects of a selective PAF receptor antagonist, SRI 63-441, during endotoxemia in sheep.
"
4.
Hypotension (Low Blood Pressure)
04/01/1990 - "
Pretreatment of the animal with PAF antagonist, SRI 63-441, markedly ameliorated the hypotension and tissue injury.
"
04/01/1987 - "
SRI 63-441 reduced the hypotension response in the rat, where the ED50 values for inhibition of MAP were 0.16 mg/kg i.v. and 0.19 mg/kg i.v. for the recovery period.
"
04/01/1987 - "
Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog.
"
01/01/1991 - "
Pretreatment with the platelet-activating factor receptor antagonist SRI 63-441 attenuated the endotoxin-induced systemic hypotension and the decrease in MABFV, and abolished the mesenteric vasodilation effect of endotoxin infusion.
"
04/01/1987 - "
In the rat model of endotoxin-induced hypotension, SRI 63-441 given 1 min after a 5 mg/kg endotoxin challenge (which produced a 52 +/- 7% decrease in MAP), reversed the systemic effects, with an ED50 of 0.18 mg/kg i.v. The ED50 for reversal 6 min after endotoxin injection was 0.01 mg/kg. These results of inhibition and reversal by SRI 63-441 strongly implicate PAF as a pivotal mediator of hypotension and shock.
"
5.
Hypoxia (Hypoxemia)
12/01/1988 - "
SRI 63-441, 20 mg.kg-1.h-1 infused for 5 h, blocked the early rise in Ppa and PVR and fall in PaO2, but had no effect on the late phase pulmonary hypertension or hypoxemia.
"
11/01/1992 - "
In addition, SRI 63-441 potentiated angiotensin II- and hypoxia-induced vasoconstrictions.
"
09/01/1992 - "
Administration of the PAF receptor antagonist SRI 63-441 or indomethacin blocked the early (0.25-0.5 h) and attenuated the later increases in PVR and Ppa; indomethacin also attenuated the increase in Pt and hypoxemia associated with TNF-alpha infusion.
"
05/01/1992 - "
Young male Sprague-Dawley rats were anesthetized with pentobarbital and divided into six experimental groups: 1) control, 2) LPS alone (2 mg/kg), 3) hypoxia alone (5% O2), 4) LPS+hypoxia, 5) WEB 2086 (PAF antagonist)+LPS+hypoxia, and 6) SRI 63-441 (PAF antagonist)+LPS+hypoxia.
"
11/01/1992 - "
We investigated the effects of two different platelet-activating factor (PAF) antagonists, SRI 63-441 and WEB 2086, on PAF-, angiotensin II-, and hypoxia-induced vasoconstrictions in isolated rat lungs perfused with a physiological salt solution.
"
Related Drugs and Biologics
1.
Indomethacin (Indometacin)
2.
Iloprost (Ventavis)
3.
Naproxen (Naprosyn)
4.
Alprazolam (Xanax)
5.
Endotoxins
6.
WEB 2086 (apafant)
7.
Platelet Activating Factor
8.
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.
ginkgolide B
10.
CV 3988
Related Therapies and Procedures
1.
Controlled Hypotension